A case of moclobemide discontinuation syndrome who predominantly presented with influenza-like symptoms is presented. Sertraline treatment did not modify the symptoms, which may suggest different mechanisms with regard to different antidepressant drug discontinuation syndromes. Implications for clinical care are reviewed.
Alvarez J C, Sanceaume M, Advenier C, Spreux-Varoquaux O (1999) Differential changes in brain and platelet 5-HAT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice. Eur Neuropsychopharmacol10: 31–36
Burkard W P, Da Prada M, Keller H H, Kettler R, Haefely W (1989) Pre-clinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry6(Suppl.): 84–88
4.
Coupland N J, Bell C J, Potokar J P (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol16: 356–362
5.
Dilsaver S C (1994) Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Safety10: 103–114
6.
Haddad P M (2001) Antidepressant discontinuation syndromes Clinical relevance, prevention and management. Drug Safety24: 183–197
7.
Hilton S, Jaber B, Ruch R (1995) Moclobemide safety: Monitoring a newly developed product in the 1990s. J Clin Psychopharmacology15(Suppl. 2): 76S–83S
8.
Nair N P, Ahmed S K, Kin N M (1993) Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatry Neurosci18: 214–225
9.
Tiller J W G, Bouwer C, Behnke K (1997) Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. Inter Clin Psychopharmacol12(Suppl. 6): S27–S30
